Abstract | BACKGROUND: METHODS:
Temozolomide was administered orally as monthly 5-day courses at doses of 200 mg/m(2)/d (patients with no prior craniospinal irradiation [CSI]) or 180 mg/m(2)/d (prior CSI). Patients with a complete (CR) or partial (PR) response or stable disease (SD) could continue temozolomide for up to 12 cycles. RESULTS: CONCLUSIONS: Although overall objective responses were limited, further exploration of temozolomide may be warranted in children with medulloblastoma and other PNETs, or in patients with low-grade astrocytoma, perhaps in a setting of less pretreatment than the patients in the current study, or in the context of multiagent therapy.
|
Authors | H Stacy Nicholson, Cynthia S Kretschmar, Mark Krailo, Mark Bernstein, Richard Kadota, Daniel Fort, Henry Friedman, Michael B Harris, Nicole Tedeschi-Blok, Claire Mazewski, Judith Sato, Gregory H Reaman |
Journal | Cancer
(Cancer)
Vol. 110
Issue 7
Pg. 1542-50
(Oct 01 2007)
ISSN: 0008-543X [Print] United States |
PMID | 17705175
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- Dacarbazine
- Temozolomide
|
Topics |
- Administration, Oral
- Adolescent
- Adult
- Antineoplastic Agents, Alkylating
(administration & dosage, adverse effects, therapeutic use)
- Astrocytoma
(drug therapy)
- Brain Neoplasms
(drug therapy)
- Central Nervous System Neoplasms
(drug therapy)
- Child
- Child, Preschool
- Dacarbazine
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Drug Administration Schedule
- Ependymoma
(drug therapy)
- Female
- Humans
- Infant
- Male
- Medulloblastoma
(drug therapy)
- Neoplasm Recurrence, Local
(drug therapy)
- Neuroectodermal Tumors, Primitive
(drug therapy)
- Temozolomide
- Treatment Outcome
|